Lilly announces plans to open Lilly Gateway Labs site in Philadelphia

Core Insights - Eli Lilly and Company is set to open a new Lilly Gateway Labs site in Philadelphia, enhancing its commitment to fostering biotech innovation in key life sciences hubs [2][3] Company Expansion - The new Gateway Labs site will span 44,000 square feet at 2300 Market, a life sciences facility developed by Breakthrough Properties, providing early-stage biotech companies with fully equipped wet lab facilities and strategic scientific engagement [2] - This expansion in Philadelphia adds to Lilly's existing Gateway Labs locations in Boston, South San Francisco, and San Diego, reinforcing its strategy to establish innovation centers in areas with strong research and entrepreneurial ecosystems [2][3] Biotech Innovation Support - Lilly Gateway Labs is part of the broader Lilly Catalyze360 initiative, which includes Lilly Ventures and other programs aimed at supporting biotech innovation through access to capital, lab space, and advanced research capabilities [3] - Since the inception of the first Gateway Labs site in 2019, resident companies have collectively raised over $3 billion, contributing to the development of more than 50 therapeutic programs [3][5] Industry Context - Philadelphia is recognized as a leading biotech innovation hub, with a history of significant contributions to vaccine development, gene therapy, and Alzheimer's research, making it an ideal location for the new Gateway Labs site [2] - The establishment of the Philadelphia site is expected to catalyze community-building among biotechs, venture partners, and other stakeholders in the life sciences sector [2]